CYP17A1 rs743572 polymorphism might contribute to endometriosis susceptibility: evidences from a case–control study

Lili Cong, PhD, Qiang Fu, PhD, Tianming Gao, PhD

Abstract
This case–control study was aimed to evaluate the influence of cytochrome P450 family 17 subfamily A member 1 (CYP17A1) gene rs743572 polymorphism for the susceptibility to endometriosis. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to genotype rs743572 polymorphism in 143 endometriosis patients and 148 healthy controls. Hardy–Weinberg equilibrium (HWE) test was utilized to detect the representativeness of the study subjects. Association strength was presented by odds ratios (ORs) with corresponding 95% confidence intervals (CIs).

Genotype distribution of rs743572 polymorphism was conformed to HWE test both in case and control groups, revealing the good representativeness of our study subjects. Significantly positive association was discovered between rs743572 TT genotype and endometriosis susceptibility ($P=0.042$, OR $=1.962$, 95% CI $=1.020–3.736$). Rs743572 T allele was more frequently discovered in cases than that in controls, revealing the enhanced susceptibility to endometriosis ($P=0.041$, OR $=1.407$, 95% CI $=1.014–1.951$). Confounding factors (age and body mass index) were utilized to adjust the results, and then we found that the association strength had no significant changes (TT vs CC, $P=0.039$, OR $=1.961$, 95% CI $=1.023–3.742$; T vs C, $P=0.038$, OR $=1.413$, 95% CI $=1.016–1.957$). But we failed to find any obvious association of rs743572 genotypes with endometriosis stages and characteristics.

T allele of rs743572 polymorphism might act as a risk factor for endometriosis, although it had no effects on the disease stages and basic features.

Abbreviations: 5′-UTR = 5′-untranslated region, BMI = body mass index, CIs = confidence intervals, CYP17 = Cytochrome P450 family 17, CYP17A1 = cytochrome P450 family 17 subfamily A member 1, ESHRE = European Society of Human Reproduction and Embryology, HWE = Hardy–Weinberg equilibrium, MRI = magnetic resonance imaging, ORs = odds ratios, PCR-RFLP = polymerase chain reaction-restriction fragment length polymorphism, SNP = single-nucleotide polymorphism.

Keywords: CYP17A1, endometriosis, polymorphism

1. Introduction
Endometriosis is a common gynecologic disease of females during childbearing period.[1] It is induced by the endometrial tissues which normally grows inside the endometrium and also grows outside of it. Its morbidity is increased in recent years.[2,3]

Although a part of endometriosis patients had no symptoms, pelvic pain and infertility are the main symptoms of endometriosis.[4] Endometriosis is not a malignant disease, but it has similar biological behaviors with malignant tumors in invasion, metastasis, and recurrence.[5] It contains 3 stages: adhesion, invasion, and angiogenesis.[6] Several hypotheses have been presented to explain the development of endometriosis. The widely accepted theories include retrograde menstruation (also known as transplantation theory), immunodeficiency, coelomic metaplasia, and Mullerianosis.[7–11] Despite the unclear pathogenesis of endometriosis, it has been considered as a complex process caused by various factors.[12–16] Hormone and cytokine activity, immune inflammation reaction, and genetic factors might all participate in the development of endometriosis.

It has been found that endometriosis is an estrogen-dependent disease.[17,18] Disorders of estrogen metabolism might be closely associated with the development of endometriosis.[19,20] Thus, enzymes which regulate the synthesis and metabolism of estrogen might participate in endometriosis onset. Cytochrome P450 family 17 (CYP17) is one of the key enzymes for steroidogenic pathway which produces estrogen.[21] In human, it is encoded by CYP17A1 (CYP17 subfamily A member 1) gene which is located at chromosome 10q24.32. CYP17 plays its 17alpha-hydroxylase and 17,20-lyase activities in endoplasmic reticulum.[22] Polymorphisms of CYP17A1 gene might alter the expression level and activity of CYP17, then resulting in the disorders of estrogen metabolism. Therefore, CYP17A1 polymorphisms might act as the risk factors for endometriosis. A widely studied single-nucleotide polymorphism (SNP) in the 5′-UTR (untranslated

---

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

Medicine (2018) 97:28(e11415)
Received: 17 February 2017 / Accepted: 12 June 2018
http://dx.doi.org/10.1097/MD.0000000000011415
Table 1

Basic characteristics.

| Characteristics       | Case n=143 (%) | Control n=148 (%) | P     |
|-----------------------|---------------|-------------------|-------|
| Age, y                | 36.42±7.63    | 36.97±8.37        | .806  |
| BMI, kg/m²            | 23.14±4.23    | 22.97±3.85        | .385  |
| Age of menarche, y    | 13.58±1.42    | 13.94±1.32        | .612  |
| Menstrual cycle, d    | 28.01±3.22    | 30.62±5.24        | .048  |
| Intravenous device use| 37 (25.87)    | 24 (16.22)        | .043  |
| Oral contraceptive use| 37 (25.87)    | 27 (18.24)        | .116  |
| Coffee                | 63 (44.06)    | 69 (46.62)        | .660  |
| Tea                   | 73 (51.05)    | 91 (61.49)        | .073  |
| Drinking              | 13 (9.09)     | 19 (12.84)        | .307  |
| Cigarette smoking     | 20 (13.99)    | 7 (4.73)          | .007  |
| Secondhand smoking    | 57 (39.86)    | 35 (23.65)        | .003  |

Drinking, alcohol consumption ≥50 g/time, and drinking frequency >2 times/week; smoking, cigarette consumption ≥1/d, and lasting >6 months.

Table 2

Association between rs743572 and endometriosis susceptibility.

| Genotype/allele | Case n=143 (%) | Control n=148 (%) | P     | OR (95%CI) | P     | OR (95%CI) |
|-----------------|---------------|-------------------|-------|-----------|-------|-----------|
| CC              | 37 (25.67)    | 50 (33.78)        | .378  | 1.275 (0.743–2.189) | .369  | 1.281 (0.748–2.191) |
| TC              | 67 (46.86)    | 71 (46.97)        | .042  | 1.952 (1.020–3.736) | .039  | 1.961 (1.023–3.742) |
| TT              | 141 (19.30)   | 171 (57.77)       | —     | —         | —     | —         |
| C               | 145 (50.70)   | 125 (42.23)       | .041  | 1.107 (1.014–1.951) | .038  | 1.413 (1.016–1.957) |
| T               | 0.453         | 0.838             |       |           |       |           |

*Adjusted by age and body mass index.

2.2. Genotyping method

Peripheral venous blood was collected from every subject in case and control groups using anticoagulative tubes which contain EDTA. Genomic DNA was extracted by the TIANamp Blood DNA Kit (TIANGEN, Beijing).

CYP17 rs743572 SNP was amplified using the primers of 5'-CATTCCGCACTCTGGA GTC-3' (forward) and 5'-AGGCTCT TGGGTTACTTG-3' (reverse). PCR process included initial degeneration at 94°C for 5 minutes, 40 cycles of degeneration at 94°C for 60 seconds, annealing at 57°C for 50 seconds, extension at 72°C for 60 seconds, then followed the final extension at 70°C for 10 minutes. PCR products of rs743572 were digested by MspAI overnight at 37°C.

2.3. Statistical analysis

Calculations were performed by PASW 18.0. Statistic significance was existed when \( P < .05 \). Hardy–Weinberg equilibrium (HWE) test was utilized to detect the goodness-of-fit of the study subjects. Continuous variables were evaluated by \( t \) test or nonparametric test. Chi-square test or Fisher exact test was utilized to assess the categorical variables. Genotype and allele frequencies were calculated by direct counting. Association between CYP17 SNPs and endometriosis susceptibility was assessed by Chi-square test, and adjusted to age and BMI using logistic regression analysis. The results were presented by odds ratios (ORs) with 95% confidence intervals (CIs).

3. Results

3.1. Basic characteristic of subjects

Endometriosis patients were classified into I (22/143), II (18/143), III (82/143), IV (21/143) stages. Age distribution and BMI had no significant difference between case and control groups (Table 1; \( P > .05 \)). Besides, age of menarche, oral contraceptive use, coffee, tea, and alcohol consumption all had similar trend between endometriosis patients and healthy controls (\( P > .05 \) for all). Although the menstrual cycle was significantly longer in controls than that in cases (\( P = .048 \)), intrauterine device use, smoking, and secondhand smoking were more frequently discovered in patients than that in controls (\( P < .05 \)).

3.2. Association between rs743572 and endometriosis susceptibility

Genotype and allele distributions of rs743572 SNP were conformed to HWE test both in case and control groups (Table 2; \( P > .05 \)), demonstrating that the study subjects could represent the general population.
CC, CT, and TT genotype frequencies of rs743572 SNP were 25.87%, 46.85%, 27.27% in cases and 33.78%, 47.97%, 18.24% in controls, respectively. In comparison with CC genotype, TT genotype was significantly associated with increased susceptibility to endometriosis (P = 0.042, OR = 1.952, 95% CI = 1.020–3.736). When adjusted by confounding factors, the association strength had no distinct alteration (P = 0.039, OR = 1.961, 95% CI = 1.023–3.742). Obviously higher frequency of rs743572 T allele has been discovered in case group than that in control group (P = 0.041), indicating that this allele was significantly associated with enhanced endometriosis susceptibility (OR = 1.407, 95% CI = 1.014–1.951). After adjustment, the association was still statistically significant (P = 0.038, OR = 1.413, 95% CI = 1.016–1.957).

3.3. Effects of rs743572 genotype on characteristics of endometriosis patients

In endometriosis patients, age of menarche was increased in TC and TT genotype carriers, and menstrual cycle was decreased in TC and TT genotype carriers, but it had no significant difference (Table 3; P > 0.05). Besides, no significant distinct has been found in other characteristics among patients carrying rs743572 genotypes (P > 0.05).

3.4. Stratified analysis based on the stages of endometriosis

Genotype distributions of rs743572 SNP in different stages of endometriosis were shown in Table 4. Genotype and allele frequencies had no significant difference between 4 endometriosis stages (P > 0.05, data not shown). We carried out the stratified analysis based on the endometriosis stages. Nevertheless, we failed to find any significant association between rs743572 and endometriosis susceptibility in every stage (P > 0.05, data not shown). These results suggested that rs743572 had no significant effects on the severity and susceptibility of endometriosis.

4. Discussion

CYP17 is the rate-limiting enzyme for the biosynthesis of steroid hormones including estrogen. Abnormal expression level of estrogen was associated with the occurrence and development of endometriosis. Mutations in CYP17A1 gene were correlated with hormone expression, and then contributed to the onset of endometriosis, breast, and prostate cancers.[23] CYP17 expression level is upregulated in patients with endometriosis than that in controls.[23] It has been considered that rs743572 SNP is related to the expression of CYP17; T allele might induce the upregulation of CYP17 in patients with prostate cancer.[23] However, the effects of rs743572 on endometriosis were not clear.

In present study, significantly higher rs743572 TT genotype frequency in case group suggested 1.952 times increased susceptibility to endometriosis. When adjusted by basic characteristics, the association strength was elevated to 1.961. Besides, 1.407 times enhanced endometriosis susceptibility was significantly associated with rs743572 T allele. Confounding factors were used to adjust the result, and then we found that correlation between rs743572 T allele and endometriosis susceptibility was increased to 1.413-fold. The conclusions were in line with the previous studies. Bozdag et al found that homozygote mutation of rs743572 had higher frequency in endometriosis patients.[26] Szczepaniska et al found that rs743572 was positively correlated with endometriosis risk.[27] The positive association has also been discovered by Hsieh et al in a Chinese population,[28] although other studies indicated that rs743572 SNP was not associated with the risk of endometriosis.[29,30] Meanwhile, no evidence has been found in the meta-analysis for the significant association between rs743572 and endometriosis risk.[31] These difference might be caused by different populations, relatively small sample size or other factors.

In present study we found that menstrual cycle, intrauterine device use, smoking, and secondhand smoking might act as risk factors for endometriosis. Menstrual cycle changes in the present study were similar to thereof in endometriosis or adenomyosis patients.[31] Adjustment result demonstrated that basic characteristics had tiny effects on endometriosis. These tiny effects combined with genetic polymorphisms contributed to the endometriosis susceptibility. Soon after, we evaluated the distributions of basic characteristics in patients carrying different rs743572 genotypes. TT genotype carriers had the shortest menstrual cycle, highest frequencies of intrauterine device use, smoking and secondhand smoking exposure, but the differences were not significant. We suggested that rs743572 might had no significant effects on the medical histories, such as age of menarche or menstrual cycle. There was no previous study focused on this topic; it should be verified in future.

In addition, we also analyzed the effects of rs743572 SNP on the severity of endometriosis. No significant effect has been discovered in rs743572 on the endometriosis severity. Stratified analysis based on the disease stages also failed to find any significant association between rs743572 and endometriosis susceptibility. Absent of statistical significance for the results probably induced by the small sample size. But a noteworthy correlation has been discovered between rs743572 and endometriosis severity in a Turkey population.[26]

### Table 3

| Genotype distributions of rs743572 for characteristics of endometriosis patients. |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Characteristics | CC n = 37(%)    | TC n = 67(%)    | TT n = 39(%)    |
| Age, y          | 35.94 ± 8.17    | 36.37 ± 7.88    | 36.95 ± 7.95    |
| BMI, kg/m²      | 22.95 ± 4.86    | 23.06 ± 4.33    | 23.35 ± 4.47    |
| Age of menarche, y | 13.14 ± 1.46   | 13.52 ± 1.39    | 13.74 ± 1.50    |
| Menstrual cycle, d | 29.85 ± 4.14    | 28.78 ± 3.94    | 27.14 ± 3.78    |
| Intrauterine device use | 9 (24.32)       | 16 (23.88)      | 12 (30.77)      |
| Oral contraceptive use | 9 (24.32)       | 17 (25.37)      | 11 (28.21)      |
| Coffee           | 16 (43.24)      | 29 (43.28)      | 18 (46.19)      |
| Tea              | 19 (51.36)      | 34 (60.75)      | 20 (51.26)      |
| Drinking         | 3 (8.11)        | 6 (9.60)        | 4 (10.26)       |
| Smoking          | 5 (13.51)       | 9 (13.43)       | 6 (15.38)       |
| Secondhand smoking | 14 (37.84)      | 27 (40.30)      | 16 (41.03)      |

### Table 4

| Genotype distributions in different stages of endometriosis. |
|-----------------|-----------------|-----------------|-----------------|
| Stages          | CC              | TC              | TT              |
| I n = 22        | 8 (36.36)       | 8 (36.36)       | 6 (27.27)       |
|                 | (24.54)         | (20.45)         |
| II n = 18       | 3 (16.67)       | 10 (55.56)      | 5 (27.28)       |
|                 | (16.44)         | (20.55)         |
| III n = 82      | 22 (26.83)      | 37 (45.12)      | 23 (28.05)      |
|                 | (81.40)         | (83.50)         |
| IV n = 21       | 3 (14.29)       | 12 (57.14)      | 6 (28.57)       |
|                 | (18.42)         | (24.57)         |
Several limitations should be admitted in present study. First, polymorphism distribution was diverse in different populations, thus our results might not be applied for other populations. Second, CYP17 expression level and activity should be detected in further studies. Third, endometriosis is a complex disease, but interactions between gene and environment factors were not performed in this study. To certify the endometriosis pathogenesis, next studies with enlarged sample size, population number, and other topic are needed in the future.

In conclusion, rs743572 T allele might predict high susceptibility to endometriosis, but it had no significant influence on characteristics and severity of endometriosis.

Author contributions
Conceptualization: Lili Cong.
Data curation: Lili Cong.
Formal analysis: Lili Cong.
Funding acquisition: Qiang Fu.
Investigation: Qiang Fu.
Methodology: Qiang Fu.
Project administration: Qiang Fu.
Resources: Qiang Fu.
Software: Qiang Fu.
Supervision: Qiang Fu.
Validation: Tianming Gao.
Visualization: Tianming Gao.
Writing – original draft: Tianming Gao.
Writing – review and editing: Tianming Gao.

References
[1] Nonthick WB. The emerging use of aromatase inhibitors for endometriosis treatment. Reprod Biol Endocrinol 2011;9:87.
[2] Child TJ, Tan SL. Endometriosis: etiology, pathogenesis and treatment. Drugs 2001;61:1735–50.
[3] Fuldeore MJ, Soliman AM. Prevalence and symptomatic burden of diagnosed endometriosis in the United States: national estimates from a cross-sectional survey of 59,411 women. Gynecol Obstet Invest 2016.
[4] Bolletti C, Coccia ME, Battistoni S, et al. Endometriosis and infertility. J Assist Reprod Genet 2010;27:441–7.
[5] Zhu T, Zhang X. [Research progress on the role of epithelial-mesenchymal transition in pathogenesis of endometriosis]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2016;45:439–45.
[6] Johnson NP, Hummelshoj L, Adamson GD, et al. World Endometriosis Society consensus on the classification of endometriosis. Hum Reprod 2017;32:215–24.
[7] Zubrzycka A, Zubrzycki M, Jancea A, et al. New Horizons in the Etiopathogenesis and Non-Invasive Diagnosis of Endometriosis. Curr Mol Med 2015;15:697–713.
[8] Azoa MO, Enarsson JF. Management of endometriosis involving the urinary tract. Semin Reprod Med 2017;35:81–7.
[9] Ren XU, Wang Y, Xu G, et al. Effect of ralapycin on endometriosis in mice. Exp Ther Med 2016;12:101–6.
[10] Sikora J, Mielczarek-Palacz A, Kondera-Anasz Z. Association of the Precursor of Interleukin-1beta and Peritoneal Inflammation-Role in Pathogenesis of Endometriosis. J Clin Lab Anal 2016;30:831–7.
[11] Signorile PG, Baldi F, Bussani R, et al. Ectopic endometrium in human foetuses is a common event and sustains the theory of mullerianiosis in the pathogenesis of endometriosis, a disease that predisposes to cancer. J Exp Clin Cancer Res 2009;28:49.
[12] Guo SW, Zhang Q, Liu X. Social psychogenic stress promotes the development of endometriosis in mouse. Reprod Biomed Online 2017;34:225–9.
[13] Zondervan KT, Kahninglu N, Morris AP, et al. Beyond Endometriosis Genome-Wide Association Study: From Genomics to Phenomics to the Patient. Semin Reprod Med 2016;34:242–54.
[14] Khan Z, Zanfagnin V, El-Nashar SA, et al. Risk factors, clinical presentation and outcomes for abdominal wall endometriosis. J Minim Invasive Gynecol 2017;24:478–84.
[15] Mowers EL, Lim CS, Skinner B, et al. Characteristics of women undergoing hysterectomy for chronic pelvic pain: prevalence and risk factors for endometriosis. J Minim Invasive Gynecol 2015;22(6S):S232.
[16] Bullon P, Navarro JM. Inflammassome as a key pathogenic mechanism in endometriosis. Curr Drug Targets 2017;18:997–1002.
[17] Kitawaki J, Kado N, Ishihara H, et al. Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol 2002;83:149–55.
[18] Abdelsame A, van Koppen CJ, Bey E, et al. Treatment of estrogen-dependent diseases: Design, synthesis and profiling of a selective 17beta-HSD1 inhibitor with sub-nanomolar IC50 for a proof-of-principle study. Eur J Med Chem 2017;127:944–57.
[19] Thakur A, Mandal NC, Banerjee S, Compounds of natural origin and acupuncture for the treatment of diseases caused by estrogen deficiency. J Acupunct Meridian Stud 2016;9:109–17.
[20] Tosti C, Biscione A, Morgante G, et al. Hormonal therapy for endometriosis: from molecular research to bedside. Eur J Obstet Gynecol Reprod Biol 2017;209:61–6.
[21] Jahromi MS, Tehrani FR, Noroozadeh M, et al. Elevated expression of steroidogenesis pathway genes; CYP17, GATA6 and StAR in prenatally androgenized rats. Gene 2016;593:167–71.
[22] Nguyen PT, Conley AJ, Sneyd J, et al. The role of enzyme compartmentalization on the regulation of steroid synthesis. J Theor Biol 2013;332:52–64.
[23] Al-Rubai’ei SH, Naji TS, Turki KM. Common variation of the CYP17 gene in Iraqi women with endometriosis disease. Genom Data 2017;11:55–9.
[24] Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005;20:2698–704.
[25] Song J, Tao ZH, Liu XY, et al. Relationship between CYP17 gene polymorphisms and risk of prostate cancer. Genet Mol Res 2016;15:15017866.
[26] Bozdag G, Alp A, Saribas Z, et al. CYP17 and CYP2C19 gene polymorphisms in patients with endometriosis. Reprod Biomed Online 2010;20:286–90.
[27] Szczepanska M, Wurstle P, Skrzypczak J, et al. Polymorphic variants of CYP17 and CYP19A and risk of infertility in endometriosis. Acta Obstet Gynecol Scand 2013;92:1188–93.
[28] Hsieh YY, Chang CC, Tse FJ, et al. Cytochrome P504c17alpha 5’-untranslated region *T/C polymorphism in endometriosis. J Genet 2004;83:189–92.
[29] Zhao X, Zong LL, Wang YF, et al. [Association of single nucleotide polymorphism in CYP17 and ERALpha genes with endometriosis risk in southern Chinese women]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2011;28:304–7.
[30] Zhao ZZ, Nyholt DR, Le L, et al. Common variation in the CYP17A1 and IFIT1 genes on chromosome 10 does not contribute to the risk of endometriosis. Open Reprod Sci J 2008;1:35–40.
[31] Chen HY, Pang LH, Yang DM, et al. Association study between CYP17 gene polymorphism and endometriosis risk: a meta-analysis. J Obset Gynecol Res 2015;41:497–504.
[32] Huang PC, Li WF, Liao PC, et al. Risk for estrogen-dependent diseases in relation to phthalate exposure and polymorphisms of CYP17A1 and estrogen receptor genes. Environ Sci Pollut Res Int 2014;21:13964–73.